financetom
Business
financetom
/
Business
/
BioVaxys Announces Planned Private Placement and Debt Settlement
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BioVaxys Announces Planned Private Placement and Debt Settlement
Jul 23, 2024 2:08 PM

04:47 PM EDT, 07/23/2024 (MT Newswires) -- BioVaxys Technology ( BVAXF ) said Tuesday it is raising up to $0.5 million in a non-brokered private placement of 10-million share units priced at $0.05 per unit.

Each unit is made up of a share and a two-year warrant to buy a second share for $0.15.

The company intends to use the proceeds for general working capital purposes.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Baidu, Uber to Deploy Autonomous Ride-Sharing Vehicles
Baidu, Uber to Deploy Autonomous Ride-Sharing Vehicles
Jul 15, 2025
08:31 AM EDT, 07/15/2025 (MT Newswires) -- Baidu ( BIDU ) and Uber Technologies ( UBER ) said Tuesday they have agreed to deploy thousands of Baidu's ( BIDU ) Apollo Go autonomous vehicles on the Uber ( UBER ) platform in various markets outside the US and mainland China. The partnership is aimed at supporting the supply of affordable...
ProKidney Says FDA Confirms Accelerated Approval Pathway for Rilparencel
ProKidney Says FDA Confirms Accelerated Approval Pathway for Rilparencel
Jul 15, 2025
08:30 AM EDT, 07/15/2025 (MT Newswires) -- ProKidney ( PROK ) said Tuesday that the US Food and Drug Administration has confirmed that the estimated glomerular filtration rate slope can be used as an endpoint to support a biologics license application for rilparencel in patients with chronic kidney disease and type 2 diabetes under the accelerated approval pathway. The regulator...
FDA staff raises eye damage concerns for GSK's blood cancer drug
FDA staff raises eye damage concerns for GSK's blood cancer drug
Jul 15, 2025
July 15 (Reuters) - The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug, when used in combination with other treatments, may cause eye damage in patients. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved